

【Press release】



ESSEX BIO-TECHNOLOGY LIMITED 億勝生物科技有限公司

(Stock Code: 1061)

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2021 Annual Meeting

Hong Kong, 30 Apr 2021

Essex Bio-Technology Ltd (“Essex” or the “Group”, Stock Code: 1061.HK) announced that the Group will be presenting the results from their research titled “**bFGF alleviated scopolamine-induced dry eye by modulation growth and inflammatory response and promoting healing process both *in vitro* and *in vivo***” at the annually held meeting(virtual) of Association and Research in Vision and Ophthalmology (ARVO).

Date and time: Thu, May 6th, 11:15 PM to Fri, May 7th, 00:45 AM(CST).

Section: Paper Abstract

Authorship: Yingluo Xiong and Malcolm Ngiam, et. al.

Presenter: YingLuo Xiong Ph.D. (Zhuhai Essex Bio-pharmaceutical CO., LTD.)

Link: <https://arvo2021.arvo.org/meetings/virtual/cPWZt2NQYXcNajDXC>

Research Briefing:

The result of the studies demonstrated that bFGF promotes normal corneal and conjunctival epithelial cell proliferation and migration. In mild inflammation environment *in vitro*, bFGF prevents cell death caused by inflammatory cytokine and matrix production. Also, bFGF significantly ameliorated dry eye inflammation and tissue damage in the scopolamine-induced dry eye animal model, even better than a classical dry eye medication, sodium hyaluronate. Collectively, we revealed the role of bFGF not only in cell proliferation and migration of ocular surface and tissue repair, but also in controlling mild eye inflammation, which may provide therapeutic value of bFGF in treatment of dry eyes.

~ End ~

About bFGF

Basic fibroblast growth factor (bFGF, or FGF-2) is an active substance in trace amount which exists in mammals and human body. FGFs, an important member of the growth factor family, are cell signaling proteins that play a positive role in multiple cellular processes including proliferation, differentiation, cell survival, cell adhesion, motility, chemotaxis, neovasculature and homeostasis. The product(s) from Essex's FGF Technology Platform provides a therapeutic with balanced level of growth factor(s) to local damaged environment, making it a safe and effective treatment for human wounds and tissue disorders.

About ARVO

The Association for Research in Vision and Ophthalmology, Inc. (ARVO) is the largest and most respected eye and vision research organization in the world. Its members include nearly 11,000 researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating, and curing its disorders. The ARVO 2021 Annual Meeting will have the theme "Revolutionary Eye and Vision Research".

About Essex

Essex Bio-Technology Limited is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 9,000 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.

Contact

Investor Relations: Investors@essex.com.cn

Media: Media@essex.com.cn